Dr. Andrew Parker has over two decades of experience in the pharmaceutical industry, spanning from preclinical development, through early clinical formulation development into late-stage development, scale-up, and commercialization. At Quotient Sciences, Andrew's focus is on Translational Pharmaceutics® and the acceleration of drug candidate progression provided through the integration of formulation development, clinical drug product manufacture, and clinical dosing activities. 

Andrew has an interest in enabling technologies for bioavailability enhancement, characterization of all delivery formats, innovative technologies, and understanding drug product structure and function relationships.  Additionally, he has advised clients in all types of clinical pharmacology study objectives, including first-in-human, drug-drug interaction studies, relative bioavailability, bioequivalence, TQT, and studies where various types of PD biomarkers and PD bio-responses (such as EEG) are part of exploratory endpoints in healthy volunteer studies.

Before joining Quotient Sciences, Andrew worked at Cooper Surgical and Healthcare as a Program Director and at Catalent as an Open Innovation Director covering two business units.  Andrew also spent 15 years at Juniper Pharma Services and Molecular Profiles CDMOs in a variety of roles combining technical and commercial knowledge, sitting at the operational and business interfaces with external clients.  

Andrew holds a PhD in physical chemistry from the University of Bristol.